Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center

BACKGROUND: Immune checkpoint inhibitors (ICIs) are a novel class of anticancer agents that have demonstrated clinical response for both solid and hematological malignancies. ICIs are associated with development of immune-related adverse events including cardiotoxicity. We estimated the incidence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Waheed, Nida, Fradley, Michael G., DeRemer, David L., Mahmoud, Ahmad, Shah, Chintan P., Langaee, Taimour Y., Lipori, Gloria P., March, Keith, Pepine, Carl J., Cooper-DeHoff, Rhonda M., Wu, Yonghui, Gong, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977591/
https://www.ncbi.nlm.nih.gov/pubmed/33736707
http://dx.doi.org/10.1186/s40959-021-00097-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977591/
https://www.ncbi.nlm.nih.gov/pubmed/33736707
http://dx.doi.org/10.1186/s40959-021-00097-9

Ejemplares similares